Targeting lipogenesis promotes the synergistic effect of the selective HDAC6 inhibitor ITF3756 with bortezomib in colon cancer cells
Overall, these results reveal a particular antitumor efficacy of the selective HDAC6 inhibitor in combination with BTZ in colon cancer cells and suggest that inhibiting lipogenesis is a useful tool to further increase the synergistic effectiveness.
Authors
- Michela Giuliano (ORCID: https://orcid.org/0000-0002-5114-6267)
- Antonietta Notaro (ORCID: https://orcid.org/0000-0002-9822-0823)
- Federica Affranchi
- Chiara Zichittella (ORCID: https://orcid.org/0000-0001-9047-1575)
- Sonia Emanuele (ORCID: https://orcid.org/0000-0003-0932-6050)
- Diana Di Liberto (ORCID: https://orcid.org/0000-0002-7327-8121)
- Giovanni Pratelli (ORCID: https://orcid.org/0000-0002-5294-2564)
- Marzia Franzò
Institutions
- University of Palermo (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.3389/fphar.2025.1706770
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi di Palermo
- Associazione Italiana per la Ricerca sul Cancro
- Italfarmaco